Applied BioCode (TPE:6598) EV-to-EBIT : -6.04 (As of May. 29, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Applied BioCode EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Applied BioCode's Enterprise Value is NT$1,402.7 Mil. Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-232.1 Mil. Therefore, Applied BioCode's EV-to-EBIT for today is -6.04.

The historical rank and industry rank for Applied BioCode's EV-to-EBIT or its related term are showing as below:

TPE:6598' s EV-to-EBIT Range Over the Past 10 Years
Min: -59.39 Med: -9.63 Max: -4.78
Current: -6.04

During the past 13 years, the highest EV-to-EBIT of Applied BioCode was -4.78. The lowest was -59.39. And the median was -9.63.

TPE:6598's EV-to-EBIT is ranked worse than
100% of 458 companies
in the Medical Devices & Instruments industry
Industry Median: 19.425 vs TPE:6598: -6.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Applied BioCode's Enterprise Value for the quarter that ended in Mar. 2025 was NT$1,346.2 Mil. Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-232.1 Mil. Applied BioCode's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -17.24%.

Applied BioCode EV-to-EBIT Historical Data

The historical data trend for Applied BioCode's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied BioCode EV-to-EBIT Chart

Applied BioCode Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

-40.48

-18.03

-9.63

-9.29

-4.75

Applied BioCode Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															-7.01	-12.18	-7.51	-4.75	-5.80

Competitive Comparison of Applied BioCode's EV-to-EBIT

For the Medical Devices subindustry, Applied BioCode's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied BioCode's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Applied BioCode's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Applied BioCode EV-to-EBIT Calculation

Applied BioCode's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1402.739	/	-232.131
	=	-6.04

Applied BioCode's current Enterprise Value is NT$1,402.7 Mil.
Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-232.1 Mil.

Applied BioCode (TPE:6598) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Applied BioCode's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	-232.131	/	1346.2062
	=	-17.24 %

Applied BioCode's Enterprise Value for the quarter that ended in Mar. 2025 was NT$1,346.2 Mil.
Applied BioCode's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-232.1 Mil.

Applied BioCode EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Applied BioCode's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied BioCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Applied BioCode Corp (TPE:6598) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12130 Mora Dr., Unit 2,, Santa Fe Springs, CA, USA, 90670

Website

https://www.apbiocode.com

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Applied BioCode Headlines

No Headlines